2min chapter

Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

CHAPTER

Insight: A Biotech Company That's Going Out of Business

Munchu, which is consensus is about $90 million bucks of revenue this year. They're trying to move it into follicular lymphoma and into first-line B cell lymphoma. And then they have this asset called Pelobrectib, which is a bat inhibitor in development for myelophabrosis. It's an overactive or malignant bone marrow that produces lots of bad cells.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode